111 [123] Le registre des cancers de Rabat 2005

[124] D. Moro Sibilot [et al]. tumeurs du poumon primitives et secondaires,items 125,139,141,157 .collége des enseignants de pneumologie, référentiel pour préparation de l ECN.

[125] Madelaine.J,Zalcman.G: Biologie des cancers bronchiques. EMC-Pneumologie 2 (2005) 9–31.

[126] Mennecier.B: Place actuelle des anti-angiogéniques dans le traitement des cancers bronchiques primitifs. Rev Mal Respir 2007; 24 : 6S198-6S205.

[127] Pierre Corvol: Bases moléculaires de l’angiogenèse tumorale. Annales de pathologie (2010) 30S, S32-S36.

[128] Keith R, Miller Y, Gemmil R, Drabkin H et al: Angiogenic squamous dysplasia in bronchiof individuals at high risk for lung cancer. Clin Cancer Res 2000; 6: 1616-25. [129] Mascaux.C: Aspects biologiques des cancers bronchiques. Revue des Maladies

Respiratoires Actualités (2014) 6, 311-319).

[130] Zalcman.G, N. Richard, E. Bergot: Les nouvelles thérapeutiques biologiques du cancer bronchique .Revue Pneumologie Clinique 2007 ; 63: 20-28.

[131] Recommandations professionnelles Cancer du poumon non à petites cellules. Collection Recommandations & référentiels, INCa, Boulogne-Billancourt, septembre 2010.

[132] Barlesi.F, Tomasini.P, Fournier.C, Greillier.L: Présentation clinique et diagnostic du cancer bronchique .Revue des Maladies Respiratoires Actualités (2014) 6, 341-345.

[133] Julien mazières, christophe hermart: Les tumeurs du poumon primitives et secondaires faculté de medecine de toulouse item 157.

[134] Bizieux-Thaminy.A, Hureaux.J, Urba.T:Cancers bronchiques primitifs: bilan diagnostique et traitement .EMC Médecine, Volume 1, Issue 1, February 2004, Pages 8-17

[135] Bellefqih.S, Khali.Jl, Mezouri. J et al: Mise au point syndrome cave supérieur d’origine malignes. Service de radiothérapie, institut national d’oncologie, université Mohammed-V Souissi, revue de pneumologie clinique 2014.

112

[136] Goldwasser.F: Les métastases osseuses au cours des cancers broncho- pulmonaires. Revue des Maladies Respiratoires Actualités (2013) 5, 538-546.

[137] Roche.A,Robinet .G: Métastases cérébrales des cancers bronchiques. Revue des Maladies Respiratoires Actualités (2014) 6, 169-172.

[138] Blanke C. Phase III trial of thoracic irradiation with or without cisplatin for locally advanced unresectable non-small-cell lung cancer: a Hoosier Oncology Group protocol. J Clin Oncol 1995; 13: 1425-9.

[139] Stephanie Heinemann, Peter Zabel, Hanz Peter Hauber: paranéoplasic syndrome in lung cancer, cancer therapy volume 6:687-689, 2008.

[140] Kerem Ozturk,Esra Soylu , Ugur Topal. Linear Atelectasis around the Hilum on Chest Radiography: A Novel Sign of Early Lung Cancer, 2018.

[141] Blanke C. Phase III trial of thoracic irradiation with or without cisplatin for locally advanced unresectable non-small-cell lung cancer: a Hoosier Oncology Group protocol. J Clin Oncol 1995; 13: 1425-9.

[142] Westeel .V, Verdoni.L: Recommandations nationales INCa-SPLF sur le bilan initial d’un cancer du poumon. Revue des Maladies Respiratoires Actualités (2012) 4, p 474-478.

[143] Ferretti.G (1, 2), Jankowski.A (1), Calizzano.A (3), Moro-Sibilot.D (2 4) et JP

Vuillez.Imagerie radiologique et TEP Scanner dans les cancers du poumon. Éditions Françaises Radiol. 2008; 89(3):403-412.

[144] Gambhir SS, Czernin J, Schwimmer J, Silverman DHS, Coleman RE, and Phelps ME.A tabulated summary of the FDG PET literature. J Nucl Med. 2001; 42(5 SUPPL.): 1S - 93S.

[145] Jean - Noël Talbot, Khaldoun Kerrou, Dany Grahek, Sona Balogova, Valérie Gounant. La TEP dans les cancers bronchopulmonaires ou pleuraux primitifs. Vol 35, N° 9-C2-2006:1387-1400.

[146] Vaylet.F, Rivière.F,Le Floch.H, A et al: 18F-FDG-TEP: sa place dans le diagnostic et la surveillancedu cancer bronchique non à petites cellules. Rev Mal Respir 2007; 24: 6S35-6S39.

113

[147] Gerard A. Silvestri et al. Methods for Staging Non-Small Cell Lung Cancer: Diagnosis and Management of Lung Cancer, 3rd Ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines, 2013; Chest 143(5):e211S‑e250S.

[148] Anthoine.D ,CHU de Nancy: les grands syndromes .endoscopie trachéobronchique. [149] T. Egenod et R. Legros, EBUS/EUS: quelle relation? Pour quel résultat?, Revue des

Maladies Respiratoires Actualités ,2017; 9(2):144-53.

[150] Didier Lardinois et al. Etiology of Solitary Extrapulmonary Positron Emission Tomography and Computed Tomography Findings in Patients with Lung Cancer, Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 2005; 23(28):6846‑53.

[151] Gerard A. Silvestri et al. Methods for Staging Non-Small Cell Lung Cancer: Diagnosis and Management of Lung Cancer, 3rd Ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines, 2013; Chest 143(5):e211S‑e250S.

[152] Steinfort DP, Vincent J, Heinze S, Antippa P, Irving LB: Comparative effectiveness of radial probe endobronchial ultrasound versus CT-guided needle biopsy for evaluation of peripheral pulmonary lesions: a randomized pragmatic trial. Respir Med 2011; 105:1704-11.

[153] Ost DE, Jim Yeung SC, Tanoue LT, Gould MK: Clinical and organizational factors in the initial evaluation of patients with lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2013; 143(5Suppl):e121S41S. [154] Roberts ME, Neville E, Berrisford RG, Antunes G, Ali NJ, Group BTSPDG:

Management of a malignant pleural effusion: British Thoracic Society Pleural Disease Guideline 2010. Thorax 2010; 65(Suppl2):ii32-40.

114

[156] Hooper C, Lee YC, Maskell N, Group BTSPG:Investigation of a unilateral pleural effusion in adults: British Thoracic Society Pleural Disease Guideline 2010. Thorax 2010;65(Suppl2):ii4 17.

[157] E. Quoix, B. Mennecier, Ph. Fraisse : Cancer bronchique primitif non à petites cellules : le bilan d’extension. Rev Mal Respir Actual 2009; 1: 347-352.

[158] . Eberhardt WEE, Mitchell A, Crowley J, Kondo H, Kim YT, Turrisi A, et al. The IASLC Lung Cancer Staging Project: Proposals for the Revision of the M Descriptors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer. J Thorac Oncol. 2015;10(11):1515‑22.

[159] N. Naqos et al, Cancers bronchiques non à petite cellule : congrès de l’ECCO/ESMO 2017, Revue de Pneumologie Clinique, mars 2018.

[160] N. Guibert, M. Delaunay, et J. Mazières, Immunothérapie et cancer du poumon : où en sommes-nous ?, Revue des Maladies Respiratoires Actualités, Cours du Groupe d’Oncologie thoracique de Langue Française, GOLF 2017, 2017; 9(2):315‑24].

[161] H. Kamoun et al. Récidives tumorales du cancer bronchopulmonaire non à petites cellules opérées, Revue des Maladies Respiratoires, 2018; 35:A206.

[162] F. Z. Ammor et al. Les résections pulmonaires bronchoplastiques: indications, techniques chirurgicales et pronostic, Revue des Maladies Respiratoires, 2018; 35:A210.

[163] T. Sobue et al. Survival for Clinical Stage I Lung Cancer Not Surgically Treated. Comparison between ScreenDetected and Symptom-Detected Cases. The Japanese Lung Cancer Screening Research Group, Cancer, 1992; 69(3):685‑92.

[164] R. A. Damhuis et P. R. Schütte, Resection Rates and Postoperative Mortality in 7,899 Patients with Lung Cancer, The European Respiratory Journal, 1996; 9(1):7‑10.

[165] Yi long Wu et al. A Randomized Trial of Systematic Nodal Dissection in Resectable Non-Small Cell Lung Cancer, Lung Cancer (Amsterdam, Netherlands), 2002; 36(1):1‑6.

115

[166] Fabrice Barlesi et al. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT), The Lancet 387, 2016; nPoP 10026: 1415‑26.

[167] Giorgio V. Scagliotti et al. Randomized Phase III Study of Surgery Alone or Surgery plus Preoperative Cisplatin and Gemcitabine in Stages IB to IIIA Non-Small-Cell Lung Cancer Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 2012; 30(2).

[168] Jean-Yves Douillard et al. Adjuvant Vinorelbine plus Cisplatin versus Observation in Patients with Completely Resected Stage IB-IIIA Non-Small-Cell Lung Cancer (Adjuvant Navelbine International Trialist Association [ANITA]): A Randomised Controlled Trial, The Lancet, 2006; Oncology 7, nPoP 9.

[169] C. Gridelli, The ELVIS Trial: A Phase III Study of Single-Agent Vinorelbine as First-Line Treatment in Elderly Patients with Advanced Non-Small Cell Lung Cancer. Elderly Lung Cancer Vinorelbine Italian Study, 2001; The Oncologist 6(1):4‑7.

[170] P. Tomasini et F. Barlesi. Thérapies moléculaires ciblées en cancérologie pulmonaire, EM-Consulte, 2017.

[171] M. Duruisseaux et T. Berghmans. Évolution et révolution dans la prise en charge systémique des cancers du poumon. La nouvelle place des immunothérapies. Revue des Maladies Respiratoires, 2018; 35(2):101‑2.

[172] Haute autorité de la santé. Institut national de la santé, guide du parcours des soins: tumeurs malignes; affection maligne du tissu lymphatique ou hématopoïétique, les cancers broncho-pulmonaires. juillet 2013.

[173] Siegel R, Naishadham D, Jemal A. A Cancer statistics, 2013, CA Cancer J Clin. 2013; 63:11-30.

[174] Underner.M, Peiffer.G, Perriot.J, Prise en charge du tabagisme, Revue des Maladies Respiratoires Actualités, 2014; 6(4):320‑34.

116

[175] Gridelli.C, the elvis trial: A Phase III Study of Single-Agent Vinorelbine as First-Line Treatment in Elderly Patients with Advanced Non-Small Cell Lung Cancer. Elderly Lung Cancer Vinorelbine Italian Study, 2001; The Oncologist 6(1):4‑7.

[176] Taylor DH, Hasselblad V, Henley SJ, Thun MJ, Sloan FA. Benefits of Smoking Cessation for longevity. American Journal of Public Health. 2002; 92(6):990-996. [177] James D. Knoke, David M. Burns, Michael J. Thun. The change in excess risk of

lung cancer attributable to smoking following smoking cessation: an examination of different analytic approaches using CPS-I data. Cancer Causes Control. 2008; 19(2):207-19.

[178] The National Lung Screening Trial Research Team, Results of Initial Low-Dose Computed Tomographic Screening for Lung Cancer, New England Journal of Medicine, 2013; 368(21):1980‑91.

[179] Silva DR, Valentini DF, Jr, Müller AM, de Almeida CP, Dalcin Pde T. Tuberculose pulmonaire et cancer du poumon: occurrence simultanée et séquentielle. J Bras Pneumol. 2013; 39 (4): 484–9.

[180] Teventiyanon T, Ratanaharathorn V, Leoparait J. Carcinome mucoépidermoïde du poumon se présentant comme une lésion cavitaire. J Med Assoc Thai. 2004; 87 (8): 988–91.

[181] Yilmaz A, Gungor S, Damadoglu E, Axoy F, Aibatly A. Coexistence d'une tumeur cancéreuse bronchique et d'une tuberculose pulmonaire dans le même lobe: un rapport de cas. Tuberk. Toraks. 2004; 52 (4): 369-72.

[182] Lubarsch O. Ueber den primaren Krebs des ileum, nebst bemerhunge uber das gleichzeitge vorkommen von krebs und tuberculose. Virchows Arch. 1888; 111:280-317.

[183] Hwa Young Lee, Jin Woo Kim, Chang Dong Yeo .A case of tuberculosis reactivation suspected of cancer progression during oral tyrosine kinase inhibitor treatment in a patient diagnosed as non-small cell lung cancer, 2017.

117

[184] Sharma V, Kerr SH, Kawar Z, Kerr DJ. Challenges of cancer control in developing countries: current status and future perspective. Future Oncol. 2011; 7:1213–22.

[185] World Health Organization. Global tuberculosis control 2011. Geneva: 2011.Sharma V, Kerr SH, Kawar Z, Kerr DJ. Challenges of cancer control in developing countries: current status and future perspective. Future Oncol. 2011; 7:1213–22.

[186] Lin WW, Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest. 2007; 117(5):1175-83.

[187] Nalbandian A, Yan BS, Pichugin A, Bronson RT, Kramnik I. Lung carcinogenesis induced by chronic tuberculosis infection: the experimental model and genetic control. Oncogene. 2009; 28(17):1928-38.

[188] Camilo Molina-Romero, Oscar Arrieta, Rogelio Hernández-Pando.

Tuberculosis and Lung Cancer, 2019.

[189] Song L, Yan W, Deng M, Song S, Zhang J, Zhao T. Aberrations in the fragile histidine triad (FHIT) gene may be involved in lung carcinogenesis in patients with chronic pulmonary tuberculosis. Tumour Biol. 2004; 25(6):270-5.

[190] Dheda K, Booth H, Huggett JF, Johnson MA, Zumla A, Rook GA. Lung remodeling in pulmonary tuberculosis. J Infect Dis. 2005; 192(7):1201-9.

Au moment d'être admis à devenir membre de la profession médicale, je